Navigation Links
Study Suggests Soy Protein May Reduce Prostate Cancer Risk
Date:10/4/2007

ST. LOUIS, Oct. 4 /PRNewswire/ -- A study published in the Oct. 1 Journal of Nutrition suggests consumption of soy protein may play a role in reducing the risk of prostate cancer, Solae notes, giving consumers another healthy reason to make soy part of their diet.

The study, "Soy protein isolate increases urinary estrogens and the ratio of 2:16 alpha-hydroxyestrone in men at high risk of prostate cancer," is believed to be the first study investigating the effects of soy protein consumption on estrogen metabolism and prostate cancer in men.

"The intent of the study was to evaluate the effects of consuming soy protein on elimination of estrogen metabolites in the urine of men at a high risk for prostate cancer," said Dr. Mindy Kurzer, lead author of the study and a professor in the Department of Food Science and Nutrition at the University of Minnesota. "After taking biopsies of prostate tissue, androgen receptors were reduced in the prostate, which is consistent with a reduced risk of prostate cancer. In addition, significantly fewer of the men who consumed soy protein progressed to cancer by the end of the six-month study. We are encouraged by the results, but more studies must be performed."

"The results of this study could be beneficial for men who are at risk of prostate cancer," said Dr. Kathryn Greaves, Group Lead, Clinical Nutrition at Solae. "If the results of this study are replicated in future studies, reducing the risk of prostate cancer may be another reason to include soy in your daily diet."

Soy has been documented to potentially improve heart health and aid in sports performance and weight management. For more information on Solae and its products, please visit http://www.solae.com.

About Solae

Solae is the world leader in developing innovative soy-based technology to the food, meat and nutritional products industries. Solae provides solutions that deliver a unique combination of functional, nutritional and economic benefits to our customers.

Headquartered in St. Louis, Missouri, USA, with annual revenue exceeding $1 billion, the company was formed through an alliance between Bunge Limited (NYSE: BG) and DuPont (NYSE: DD). For more information, visit http://www.solae.com.


'/>"/>
SOURCE Solae
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... 2016 Nueterra, the nation,s largest ... the development of equity partnerships and focused ... divided its interests between two new companies—NueHealth ... continue the founding company,s private equity investment ... national system of integrated provider networks that ...
(Date:2/8/2016)... http://www.researchandmarkets.com/research/x6mkjm/knee ) has announced ... Market by Product Type (Primary (Cemented & Cementless), ... Eu-5, Japan, Bric, Turkey, Indonesia - Global Analysis ... offering. --> http://www.researchandmarkets.com/research/x6mkjm/knee ) has ... Devices Market by Product Type (Primary (Cemented & ...
(Date:2/8/2016)... Feb. 8, 2016  Avista Pharma Solutions ("Avista Pharma") ... as Chief Financial Officer (CFO). Mr. Setzer is a ... experience in various roles within growing technology and life ... as the Executive Director of Finance at INC Research, ... Raleigh, NC . Previously, Mr. Setzer served as ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... 2016 , ... Remember the old saying “rub some dirt on it”? Perhaps ... of “Calcium Bentonite Clay” the health benefits of integrating clay into a daily diet ... , A former motivational speaker, Perry A~ has since dedicated her life to learning ...
(Date:2/8/2016)... ... 08, 2016 , ... The Association of Home Care Coding ... Home Health and Hospice ICD-10 Transition Workgroup are working closely with the American ... clarifications, to address concerns over the use of 'A' as the seventh character ...
(Date:2/8/2016)... , ... February 08, 2016 , ... ... only four states in the U.S. require dental technicians to be certified or ... the dental industry, NADL created the “What’s In Your Mouth?” campaign to inform ...
(Date:2/6/2016)... , ... February 06, 2016 ... ... 303-368-6225 , MEDIA ADVISORY: 5000 PERIOPERATIVE NURSES EXPECTED AT AORN SURGICAL CONFERENCE ... perioperative nurses in the world with an estimated 5000 perioperative nurses in ...
(Date:2/5/2016)... Florida (PRWEB) , ... February 05, 2016 , ... Steven ... event he has completed every year since it started in 2003. This year, he ... the attention of fellow runners and NBA team the Miami Heat. , This Sunday, ...
Breaking Medicine News(10 mins):